Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rSIFN-co in Advanced Solid Tumors
NCT02464007Phase 1Terminated
- Sponsor
- Sichuan Huiyang Life Engineering
- Start
- Jan 2016
- Primary completion
- Nov 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of recombinant super-compound interferon in solid tumor, melanoma, kidney cancer and 4 more, sponsored by Sichuan Huiyang Life Engineering. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2016; status: terminated.
02
Drugs
recombinant super-compound interferon
03
Conditions
solid tumormelanomakidney cancerlung cancercolorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT02464007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02464007.